For Quick Alerts
ALLOW NOTIFICATIONS  
For Daily Alerts

Sun Pharma Stock Up, Settles Patent Litigation For Generic Revlimid

|

Sun Pharmaceutical Industries Limited along with one of its wholly owned subsidiaries today announced that they have reached an agreement with Celgene Corporation (Celgene), a wholly-owned subsidiary of Bristol Myers Squibb, to resolve the patent litigation regarding submission of an Abbreviated New Drug Application (ANDA) for a generic version of Revlimid (lenalidomide capsules) in the US.

 

"Pursuant to the terms of the settlement, Celgene will grant Sun Pharma a license to Celgene's patents required to manufacture and sell (subject to USFDA approval) certain limited quantity of generic lenalidomide capsules in the US beginning on a confidential date that is sometime after March 2022. In addition, the license will also allow Sun Pharma to manufacture and sell an unlimited quantity of generic lenalidomide capsules in the US beginning January 31, 2026. As a result of the settlement, all Hatch-Waxman litigation between Sun Pharma and Celgene, regarding the Revlimid patents, will be dismissed. Additional details regarding the settlement are confidential. The agreement is subject to customary regulatory approvals," the company said in an exchange filing.

The stock of Sun Pharma was marginally higher at Rs 671.60 in trade.

 

Sun Pharma Stock Up, Settles Patent Litigation For Generic Revlimid

Read more about: sun pharma
Story first published: Tuesday, June 22, 2021, 12:11 [IST]
Company Search
Get Instant News Updates
Enable
x
Notification Settings X
Time Settings
Done
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X